These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1015 related articles for article (PubMed ID: 34746689)

  • 1. Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern.
    Wang Q; Nair MS; Anang S; Zhang S; Nguyen H; Huang Y; Liu L; Ho DD; Sodroski JG
    iScience; 2021 Nov; 24(11):103393. PubMed ID: 34746689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of SARS-CoV-2 Spike G614 Variant Surpasses That of the D614 Variant after Cold Storage.
    Huang SY; Kung YA; Huang PN; Chang SY; Gong YN; Han YJ; Chiang HJ; Liu KT; Lee KM; Chang CY; Chang CC; Huang CG; Shih SR
    mSphere; 2021 Mar; 6(2):. PubMed ID: 33789940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529.
    Wang Q; Anang S; Iketani S; Guo Y; Liu L; Katsamba PS; Shapiro L; Ho DD; Sodroski JG
    Cell Rep; 2022 Jun; 39(11):110924. PubMed ID: 35658975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants.
    Gellenoncourt S; Saunders N; Robinot R; Auguste L; Rajah MM; Kervevan J; Jeger-Madiot R; Staropoli I; Planchais C; Mouquet H; Buchrieser J; Schwartz O; Chakrabarti LA
    J Virol; 2022 Oct; 96(19):e0130122. PubMed ID: 36121299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies.
    Tada T; Dcosta BM; Samanovic-Golden M; Herati RS; Cornelius A; Mulligan MJ; Landau NR
    bioRxiv; 2021 Feb; ():. PubMed ID: 33564768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity.
    Zhang L; Jackson CB; Mou H; Ojha A; Rangarajan ES; Izard T; Farzan M; Choe H
    bioRxiv; 2020 Jun; ():. PubMed ID: 32587973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging SARS-CoV-2 variants of concern.
    Sanyaolu A; Okorie C; Marinkovic A; Haider N; Abbasi AF; Jaferi U; Prakash S; Balendra V
    Ther Adv Infect Dis; 2021; 8():20499361211024372. PubMed ID: 34211709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
    Planas D; Bruel T; Grzelak L; Guivel-Benhassine F; Staropoli I; Porrot F; Planchais C; Buchrieser J; Rajah MM; Bishop E; Albert M; Donati F; Prot M; Behillil S; Enouf V; Maquart M; Smati-Lafarge M; Varon E; Schortgen F; Yahyaoui L; Gonzalez M; De Sèze J; Péré H; Veyer D; Sève A; Simon-Lorière E; Fafi-Kremer S; Stefic K; Mouquet H; Hocqueloux L; van der Werf S; Prazuck T; Schwartz O
    Nat Med; 2021 May; 27(5):917-924. PubMed ID: 33772244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.
    Wu K; Werner AP; Moliva JI; Koch M; Choi A; Stewart-Jones GBE; Bennett H; Boyoglu-Barnum S; Shi W; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
    bioRxiv; 2021 Jan; ():. PubMed ID: 33501442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants.
    Wang Q; Ye SB; Zhou ZJ; Li JY; Lv JZ; Hu B; Yuan S; Qiu Y; Ge XY
    J Med Virol; 2023 Jan; 95(1):e28116. PubMed ID: 36056469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity.
    Bhattacharya M; Chatterjee S; Sharma AR; Agoramoorthy G; Chakraborty C
    Appl Microbiol Biotechnol; 2021 Dec; 105(24):9035-9045. PubMed ID: 34755213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity.
    Gong SY; Chatterjee D; Richard J; Prévost J; Tauzin A; Gasser R; Bo Y; Vézina D; Goyette G; Gendron-Lepage G; Medjahed H; Roger M; Côté M; Finzi A
    Virology; 2021 Nov; 563():134-145. PubMed ID: 34536797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization.
    Tang H; Gao L; Wu Z; Meng F; Zhao X; Shao Y; Hou G; Du X; Qin FX
    Front Immunol; 2022; 13():836232. PubMed ID: 35371108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Consequences of Variation in SARS-CoV-2 B.1.1.7.
    Ostrov DA
    J Cell Immunol; 2021; 3(2):103-108. PubMed ID: 33969357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
    Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
    J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.